Results

1–9 of 9 results for Nancy M. Holekamp

Evaluating ANX007, a Novel C1q Inhibitor, in the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration: The ARCHER Study
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2021
Becoming a Clinical Trialist
Nancy M. Holekamp, MD, FASRS
Updates from the Field
2022
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2020
What Do the HARBOR Data Reveal About the Relationship Between the Drying of Subretinal and Intraretinal Fluid and Associated Vision Outcomes?
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2019
AMD Neovascular Expert Panel
Robert L. Avery, MD
Nizar S Abdelfattah, M.D.
Nancy M. Holekamp, MD, FASRS
Peter K. Kaiser, MD FASRS
Pravin U. Dugel, MD
Annual Meeting Talks
2016
2 Real-World Analyses of Treatment Burden Associated With Intravitreal Injections for DME Prior to 0.2 mcg/Day Fluocinolone Acetonide (FAc)
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2018
Understanding the Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Baseline Data from Proxima A
Nancy M. Holekamp, MD, FASRS
On Demand Cases, Courses, and Papers
2017
Genetic Variants Associated With Anti-VEGF Drug Response in Neovascular AMD Patients in the View Trial
Nancy M. Holekamp, MD, FASRS
Updates from the Field
2016
Ethics in Retina: A Discussion on the Ethical Considerations in Industry Relationships and Informed Consent
Nancy M. Holekamp, MD, FASRS
J. Michael Jumper, MD, FASRS
Paul Chan
Adrienne W. Scott, MD, FASRS
Webinars and Journal Clubs
2017